Targeted Oncology

Dr Mayer on Giredestrant's Success in Early Breast Cancer

Erika Mayer, MD, MPH, Dana-Farber Cancer Institute, discusses the exciting findings of the phase 3 lidERA study investigating ...
Cantech Letter

BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer

BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”), a clinical stage biotechnology ...

Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer

Eli Lilly and Company (NYSE: LLY) today announced updated results from the Phase 3 EMBER-3 study of Inluriyo (imlunestrant), an oral estrogen receptor antagonist, in patients with estrogen receptor ...
Nature

Alternative splicing articles from across Nature Portfolio

Alternative splicing is a process that enables a messenger RNA (mRNA) to direct synthesis of different protein variants (isoforms) that may have different cellular functions or properties. It occurs ...
PC Magazine

Don’t Just Google It: Smarter Search Engines to Try for 2026

Are you worried about online privacy? Not a fan of anticompetitive practices? Maybe you just want a new take on web search? These 12 search engines beat Google in many ways. I've been testing PC and ...